| Name | Title | Contact Details |
|---|
Carana Corporation is one of the leading companies in Business Services industry. Carana Corporation is based in Arlington, VA. You can find more information on Carana Corporation at www.carana.com
As the authority in authentication solutions, Authentix helps you thrive in supply and distribution chain complexity. We provide advanced authentication solutions for governments, central banks and commercial products, ensuring local economies grow, banknote security remains intact and commercial products have robust market opportunities. Specifically, we offer the following services and solutions: • Governments: Authentix works with governments to ensure authentic products are sold in-country to benefit law abiding citizens – not criminals. Fuel authentication and tax stamp solutions enable governments to collect more excise taxes without raising taxes for the benefit of citizens and legitimate industries. • Central Banks: Authentix develops and implements advanced, Level 3 authentication technologies and high-speed sensors. These solutions safeguard banknote security and support quality initiatives, providing central banks greater flexibility to maximize control and increase efficiencies in their operations. • Commercial Products: Authentix`s advanced solutions protect manufacturers in the oil and gas, pharmaceutical,agrochemical and consumer product industries. These solutions mitigate risks to promote revenue growth and gain competitive advantage, protecting both the brand and product in complex supply and distribution chains. The partnership approach and proven sector expertise of Authentix inspires proactive innovation. We invite you to experience the Authentix advantage. Headquartered in Dallas, Texas USA, Authentix has offices in the US, UK and Africa serving clients worldwide.
Advantage Direct is a Milwaukee, WI-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.
Davis and Associates is a Omaha, NE-based company in the Business Services sector.